Bucolome

Bucolome
Clinical data
Other names	Bucolome, Paramidine
AHFS/Drugs.com	International Drug Names
ATC code	none;
Identifiers
	IUPAC name 5-butyl-1-cyclohexyl-1,3-diazinane-2,4,6-trione;
CAS Number	841-73-6;
PubChem CID	2461;
ChemSpider	2367 ;
UNII	9T08RAL174;
ChEBI	CHEBI:31314 ;
ChEMBL	ChEMBL2106136;
CompTox Dashboard (EPA)	DTXSID4048854 ;
ECHA InfoCard	100.011.515
Chemical and physical data
Formula	C14H22N2O3
Molar mass	266.341 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCC1C(=O)NC(=O)N(C1=O)C2CCCCC2;
	InChI InChI=1S/C14H22N2O3/c1-2-3-9-11-12(17)15-14(19)16(13(11)18)10-7-5-4-6-8-10/h10-11H,2-9H2,1H3,(H,15,17,19) ; Key:DVEQCIBLXRSYPH-UHFFFAOYSA-N ;
	(verify)

Bucolome (Paramidine) is a barbiturate derivative. Unlike most barbiturates it does not have any significant sedative or hypnotic effects, but instead acts as an analgesic and antiinflammatory. It also acts as a CYP2C9 inhibitor and reduces the metabolism of several commonly used drugs, which makes it useful for potentiating or extending the duration of action of those drugs, or reducing the production of unwanted metabolites.^[1]^[2]^[3]

References[edit]

^ Takamura N, Maruyama T, Chosa E, Kawai K, Tsutsumi Y, Uryu Y, et al. (April 2005). "Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furosemide: potential for use of bucolome to restore diuretic response in nephrotic syndrome". Drug Metabolism and Disposition. 33 (4): 596–602. CiteSeerX 10.1.1.658.6194. doi:10.1124/dmd.104.002782. PMID 15640375. S2CID 1184330.
^ Osawa M, Hada N, Matsumoto K, Hasegawa T, Kobayashi D, Morimoto Y, et al. (April 2005). "Usefulness of coadministration of bucolome in warfarin therapy: pharmacokinetic and pharmacodynamic analysis using outpatient prescriptions". International Journal of Pharmaceutics. 293 (1–2): 43–9. doi:10.1016/j.ijpharm.2004.12.009. PMID 15778043.
^ Kobayashi M, Takagi M, Fukumoto K, Kato R, Tanaka K, Ueno K (2008). "The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan". Drug Metabolism and Pharmacokinetics. 23 (2): 115–9. doi:10.2133/dmpk.23.115. PMID 18445991.

This analgesic-related article is a stub. You can help Wikipedia by expanding it.

[1] Takamura N, Maruyama T, Chosa E, Kawai K, Tsutsumi Y, Uryu Y, et al. (April 2005). "Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furosemide: potential for use of bucolome to restore diuretic response in nephrotic syndrome". Drug Metabolism and Disposition. 33 (4): 596–602. CiteSeerX 10.1.1.658.6194. doi:10.1124/dmd.104.002782. PMID 15640375. S2CID 1184330.

[2] Osawa M, Hada N, Matsumoto K, Hasegawa T, Kobayashi D, Morimoto Y, et al. (April 2005). "Usefulness of coadministration of bucolome in warfarin therapy: pharmacokinetic and pharmacodynamic analysis using outpatient prescriptions". International Journal of Pharmaceutics. 293 (1–2): 43–9. doi:10.1016/j.ijpharm.2004.12.009. PMID 15778043.

[3] Kobayashi M, Takagi M, Fukumoto K, Kato R, Tanaka K, Ueno K (2008). "The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan". Drug Metabolism and Pharmacokinetics. 23 (2): 115–9. doi:10.2133/dmpk.23.115. PMID 18445991.

[1]

[2]

[3]

v t e Non-steroidal anti-inflammatory drugs (NSAIDs) (primarily M01A and M02A, also N02BA)
pyrazolones / pyrazolidines	Aminophenazone Ampyrone Azapropazone Clofezone Difenamizole Famprofazone Feprazone Kebuzone Metamizole Mofebutazone Morazone Nifenazone Oxyphenbutazone Phenazone Phenylbutazone Propyphenazone Sulfinpyrazone Suxibuzone^‡
salicylates	Aspirin (acetylsalicylic acid)^# Aloxiprin Benorylate Carbasalate calcium Diflunisal Dipyrocetyl Ethenzamide Guacetisal Magnesium salicylate Methyl salicylate Salsalate Salicin Salicylamide Salicylic acid (salicylate) Sodium salicylate
acetic acid derivatives and related substances	Aceclofenac Acemetacin Alclofenac Amfenac Bendazac Bromfenac Bufexamac Bumadizone Diclofenac Difenpiramide Etodolac Felbinac Fenclozic acid Fentiazac Indometacin Indometacin farnesil Isoxepac Ketorolac Lonazolac Mofezolac Oxametacin Prodolic acid Proglumetacin Sulindac Tiopinac Tolmetin Zomepirac^†
oxicams	Ampiroxicam Droxicam Isoxicam Lornoxicam Meloxicam Piroxicam Pivoxicam Tenoxicam
propionic acid derivatives (profens)	Alminoprofen Benoxaprofen^† Carprofen^‡ Dexibuprofen Dexketoprofen Fenbufen Fenoprofen Flunoxaprofen Flurbiprofen Ibuprofen^# Ibuproxam Indoprofen^† Ketoprofen Loxoprofen Miroprofen Naproxen Oxaprozin Pelubiprofen Piketoprofen Pirprofen Suprofen Tarenflurbil Tepoxalin^‡ Tiaprofenic acid Vedaprofen^‡ Zaltoprofen COX-inhibiting nitric oxide donator: Naproxcinod
n-arylanthranilic acids (fenamates)	Azapropazone Clonixin Etofenamate Floctafenine Flufenamic acid Flunixin Flutiazin Glafenine^† Meclofenamic acid Mefenamic acid Morniflumate Niflumic acid Tolfenamic acid
COX-2 inhibitors (coxibs)	Apricoxib Celecoxib (+tramadol) Cimicoxib^‡ Deracoxib^‡ Etoricoxib Firocoxib^‡ Lumiracoxib^† Mavacoxib^‡ Parecoxib Robenacoxib^‡ Rofecoxib^† Valdecoxib^†
other	Aminopropionitrile Benzydamine Chondroitin sulfate Diacerein Fluproquazone Glucosamine Glycosaminoglycan Hyperforin Nabumetone Nimesulide Oxaceprol Proquazone Superoxide dismutase / orgotein Tenidap
NSAID combinations	Ibuprofen/famotidine Ibuprofen/hydrocodone Ibuprofen/oxycodone Ibuprofen/paracetamol Meloxicam/bupivacaine Naproxen/diphenhydramine Naproxen/esomeprazole
Key: underline indicates initially developed first-in-class compound of specific group; ^#WHO-Essential Medicines; ^†withdrawn drugs; ^‡veterinary use.
category commons portal